Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Côte d'Ivoire.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
12
2022
accepted:
10
05
2023
medline:
8
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
epublish
Résumé
Although seroprevalence studies have demonstrated the wide circulation of SARS-COV-2 in African countries, the impact on population health in these settings is still poorly understood. Using representative samples of the general population, we evaluated retrospective mortality and seroprevalence of anti-SARS-CoV-2 antibodies in Lubumbashi and Abidjan. The studies included retrospective mortality surveys and nested anti-SARS-CoV-2 antibody prevalence surveys. In Lubumbashi the study took place during April-May 2021 and in Abidjan the survey was implemented in two phases: July-August 2021 and October-November 2021. Crude mortality rates were stratified between pre-pandemic and pandemic periods and further investigated by age group and COVID waves. Anti-SARS-CoV-2 seroprevalence was quantified by rapid diagnostic testing (RDT) and laboratory-based testing (ELISA in Lubumbashi and ECLIA in Abidjan). In Lubumbashi, the crude mortality rate (CMR) increased from 0.08 deaths per 10 000 persons per day (pre-pandemic) to 0.20 deaths per 10 000 persons per day (pandemic period). Increases were particularly pronounced among <5 years old. In Abidjan, no overall increase was observed during the pandemic period (pre-pandemic: 0.05 deaths per 10 000 persons per day; pandemic: 0.07 deaths per 10 000 persons per day). However, an increase was observed during the third wave (0.11 deaths per 10 000 persons per day). The estimated seroprevalence in Lubumbashi was 15.7% (RDT) and 43.2% (laboratory-based). In Abidjan, the estimated seroprevalence was 17.4% (RDT) and 72.9% (laboratory-based) during the first phase of the survey and 38.8% (RDT) and 82.2% (laboratory-based) during the second phase of the survey. Although circulation of SARS-CoV-2 seems to have been extensive in both settings, the public health impact varied. The increases, particularly among the youngest age group, suggest indirect impacts of COVID and the pandemic on population health. The seroprevalence results confirmed substantial underdetection of cases through the national surveillance systems.
Identifiants
pubmed: 37289736
doi: 10.1371/journal.pgph.0001457
pii: PGPH-D-22-01970
pmc: PMC10249894
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0001457Informations de copyright
Copyright: © 2023 Simons et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Emerg Infect Dis. 2022 May;28(5):1026-1030
pubmed: 35450565
Euro Surveill. 2022 Feb;27(7):
pubmed: 35177167
Glob Health Res Policy. 2022 Jul 20;7(1):20
pubmed: 35854345
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
Lancet Glob Health. 2021 May;9(5):e588-e589
pubmed: 33609481
Int J Infect Dis. 2021 Jan;102:483-488
pubmed: 33010461
Science. 2022 Oct 7;378(6615):eabq5358
pubmed: 36108049
Sci Rep. 2022 Nov 3;12(1):18559
pubmed: 36329082
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35998978
Am J Trop Med Hyg. 2021 Mar 18;104(5):1709-1712
pubmed: 33735104
Clin Microbiol Infect. 2021 Jan 20;:
pubmed: 33482352
Clin Infect Dis. 2022 Mar 9;74(5):882-890
pubmed: 34089598
Int J Infect Dis. 2022 Sep;122:136-143
pubmed: 35598737
PLOS Glob Public Health. 2022 Nov 9;2(11):e0000767
pubmed: 36962647
PLoS Med. 2022 Aug 30;19(8):e1004070
pubmed: 36040910
J Med Virol. 2021 Apr;93(4):2196-2203
pubmed: 33107601
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472
pubmed: 34293141
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
J Infect. 2021 May;82(5):162-169
pubmed: 33766553
J Virol Methods. 2021 Apr;290:114067
pubmed: 33476707
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347